Onderneming BioLineRX Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
IL0011015182
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
ILS in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
License
96,0
%
| - | - | 17 | 96,0 % | - |
Oncology and Hematology
4,0
%
| 0 | nan % | 1 | 4,0 % | - |
Verkoop per regio
ILS in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Israel
100,0
%
| 0 | nan % | 18 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 24-05-09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01-01-09 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-17 |
John Lacey
IRC | Investor Relations Contact | - | - |
Asaf Aloni
PRN | Corporate Officer/Principal | - | - |
Tali Yaron Dalah
AUD | Comptroller/Controller/Auditor | 46 | - |
Ella Sorani
PRN | Corporate Officer/Principal | 56 | 01-02-17 |
Holly May
PRN | Corporate Officer/Principal | - | 16-06-22 |
Corporate Officer/Principal | - | 01-08-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24-02-14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01-01-10 |
Aharon Schwartz
CHM | Chairman | 80 | 01-01-04 |
Director/Board Member | 65 | 19-08-13 | |
Raf Hofstein
BRD | Director/Board Member | 75 | 01-01-03 |
Rami Dar
BRD | Director/Board Member | 67 | 01-07-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 086 589 165 | 1 086 589 164 ( 100,00 %) | 0 | 100,00 % |
Bedrijfsgegevens
BioLineRx Ltd.
Modi'in Technology Park 2 HaMa'ayan Street
7177871, Modi'in
+972 8 642 9100
http://www.biolinerx.com![Adres BioLineRX Ltd.](https://cdn.zonebourse.com/static/address/10619776.png)
Sector
Verkoop per activiteit
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,63% | 127 mld. | |
+25,15% | 27,67 mld. | |
-20,17% | 20,33 mld. | |
-17,29% | 16,79 mld. | |
-18,07% | 15,63 mld. | |
-47,70% | 14,65 mld. | |
+11,92% | 14,84 mld. | |
+58,32% | 14,43 mld. | |
+149,98% | 12,49 mld. |